Drug Trial Radar · NCT05425732
Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)
Last checked: Nov 19, 2026Latest source record: Oct 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,663
Actual
Start
Jul 13, 2022
Primary completion
May 18, 2023
Study completion May 18, 2023
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jun 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a phase 3, randomized, double-blind, active comparator-controlled study of the safety, tolerability, and immunogenicity of V116 compared to PCV20 (pneumococcal 20-valent conjugate vaccine (\[Prevnar 20™ / APEXXNAR™\]) in pneumococcal vaccine-naïve adults. It is hypothesized that V116 is noninferior to PCV20 for the common serotypes and superior to PCV20 for the unique serotypes as assessed by serotype specific opsonophagocytic activity (OPA) 30 days postvaccination. It is also hypothesized that V116 in participants 18 to 49 years of age immunobridges to V116 in participants 50 to 64 years of age as assessed by serotype specific OPA geometric mean titers (GMTs) 30 days postvaccination for all 21 serotypes in V116. Participants ≥50 years of age will be enrolled in Cohort 1, and participants 18 to 49 years of age will be enrolled in Cohort 2.
Conditions
- Pneumococcal Infection
Interventions
V116Biological
0.5 mL injection solution in prefilled syringe containing 4 μg of each PnPs antigen (3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B) given by intramuscular (IM) injection.
PCV20Biological
0.5 mL injection suspension in prefilled syringe containing 2.2 μg of each PnPs antigen (1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F) and 4.4 μg of PnPs antigen 6B.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Solicited Injection-site Adverse Events (AEs)Time frame: Up to 5 days post-vaccination
- Percentage of Participants With Solicited Systemic AEsTime frame: Up to 5 days post-vaccination
- Percentage of Participants With Vaccine-related Serious AE (SAE)Time frame: Up to 194 days post-vaccination
- Serotype Specific Opsonophagocytic (OPA) Geometric Mean Titers (GMTs) in Cohort 1 Only, for the Pneumococcal Serotypes Contained in V116 and PCV20Time frame: Day 30 post-vaccination
- Percentage of Participants With ≥4-fold Change From Baseline in Serotype Specific OPA Responses in Cohort 1 Only for the 11 Unique Pneumococcal Serotypes Contained in V116Time frame: Baseline and Day 30 post-vaccination
- Serotype Specific OPA GMTs in Participants 18-49 Years and Participants 50-64 Years for the Pneumococcal Serotypes Contained in V116Time frame: Day 30 post-vaccination
Locations
112 sites in 11 countries. Site status is shown where the registry gives one.
Central Research Associates ( Site 0067)
Birmingham, Alabama
Lenzmeier Family Medicine/CCT Research ( Site 0006)
Glendale, Arizona
Desert Clinical Research/ CCT Research ( Site 0040)
Mesa, Arizona
Foothills Research Center/ CCT Research ( Site 0021)
Phoenix, Arizona
Fiel Family and Sports Medicine, PC/CCT Research ( Site 0003)
Tempe, Arizona
Baptist Health Center For Clinical Research ( Site 0019)
Little Rock, Arkansas
Southland Clinical Research Center-Research ( Site 0054)
Fountain Valley, California
Sunwise Clinical Research ( Site 0024)
Lafayette, California
Chemidox Clinical Trials ( Site 0048)
Lancaster, California
Paradigm Clinical Research Centers, Inc ( Site 0018)
Redding, California
Peninsula Research Associates ( Site 0079)
Rolling Hills Estates, California
Acclaim Clinical Research ( Site 0083)
San Diego, California
Millennium Clinical Trials ( Site 0013)
Simi Valley, California
Lynn Institute of Denver ( Site 0012)
Aurora, Colorado
Paradigm Clinical Research Centers, Inc ( Site 0027)
Wheat Ridge, Colorado
JEM Research Institute ( Site 0072)
Atlantis, Florida
Alliance for Multispecialty Research, LLC ( Site 0015)
Coral Gables, Florida
Hillcrest Medical Research ( Site 0049)
DeLand, Florida
East Coast Institute for Research, LLC ( Site 0070)
Jacksonville, Florida
East Coast Institute for Research ( Site 0071)
Lake City, Florida
L&C Professional Medical Research Institute ( Site 0025)
Miami, Florida
Advanced Medical Research Institute ( Site 0014)
Miami, Florida
Headlands Research Orlando ( Site 0031)
Orlando, Florida
Genesis Clinical Research, LLC ( Site 0016)
Tampa, Florida
Clinical Research Trials of Florida ( Site 0007)
Tampa, Florida
Palm Beach Research Center ( Site 0060)
West Palm Beach, Florida
Clinical Research Prime ( Site 0010)
Idaho Falls, Idaho
Solaris Clinical Research ( Site 0008)
Meridian, Idaho
Versailles Family Medicine / CCT Research ( Site 0063)
Versailles, Kentucky
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division ( Site 0038)
Troy, Michigan
Alliance for Multispecialty Research, LLC ( Site 0026)
Kansas City, Missouri
Skyline Medical Center/CCT Research ( Site 0028)
Elkhorn, Nebraska
Methodist Physicians Clinic/CCT Research ( Site 0058)
Fremont, Nebraska
Meridian Clinical Research, LLC ( Site 0045)
Norfolk, Nebraska
Healor Primary Care / CCT Research ( Site 0056)
Las Vegas, Nevada
Excel Clinical Research, LLC ( Site 0077)
Las Vegas, Nevada
Santa Rosa Medical Centers of Nevada / CCT Research ( Site 0029)
Las Vegas, Nevada
Smith Allergy & Asthma Specialists-Corning Center for Clinical Research ( Site 0032)
Horseheads, New York
Aventiv Research Inc ( Site 0044)
Columbus, Ohio
Advanced Medical Research ( Site 0002)
Maumee, Ohio
Showing 40 of 112 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.